Psychoactivity and abuse potential of sumatriptan

Area of Science:

• Pharmacology
• Neuroscience
• Clinical Psychology

Background:

• Sumatriptan is a selective 5-HT1D receptor agonist used for treating migraines and cluster headaches.
• Understanding the psychoactive profile and abuse potential of therapeutic drugs is crucial for public health and safety.

Purpose of the Study:

• To evaluate the psychoactive effects and abuse liability of sumatriptan.
• To compare the subjective and physiological responses to sumatriptan with those of morphine, a known drug of abuse.

Main Methods:

• A double-blind, Latin-square crossover study involving 12 male subjects with a history of substance abuse.
• Administration of subcutaneous placebo, sumatriptan (8 and 16 mg), and morphine (10 and 20 mg).
• Assessment of subjective, behavioral, and physiological responses, including Addiction Research Center Inventory (ARCI) scales and miosis.

Main Results:

• Sumatriptan demonstrated psychoactivity and was distinguishable from placebo.
• A dose-related decrease in euphoria scores and an increase in scores for apathetic sedation and disliking were observed with sumatriptan.
• No significant changes in heart rate, blood pressure, or pupil size were noted for sumatriptan.
• Morphine produced expected dose-response effects consistent with its known reinforcing and physiological impacts.

Conclusions:

• Sumatriptan exhibits psychoactive properties but does not appear to be a prototypic drug of abuse.
• The findings suggest that sumatriptan has a low potential for abuse.
• Further research may explore the long-term implications of sumatriptan's psychoactive effects.